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Central Nervous System Delivery of the Antipsychotic
Olanzapine Induces Hepatic Insulin Resistance
Paulo J.F. Martins, Michael Haas, and Silvana Obici
OBJECTIVE—Olanzapine (OLZ) is an atypical antipsychotic
whose clinical efﬁcacy is hampered by side effects including
weight gain and diabetes. Recent evidence shows that OLZ alters
insulin sensitivity independent of changes in body weight and
composition. The present study addresses whether OLZ-induced
insulin resistance is driven by its central actions.
RESEARCH DESIGN AND METHODS—Sprague-Dawley rats
received an intravenous (OLZ-IV group) or intracerebroventric-
ular (OLZ-ICV group) infusion of OLZ or vehicle. Glucose kinet-
ics were assessed before (basal period) and during euglycemic-
hyperinsulinemic clamp studies.
RESULTS—OLZ-IV caused a transient increase in glycemia and
a higher rate of glucose appearance (Ra) in the basal period.
During the hyperinsulinemic clamp, the glucose infusion rate
(GIR) required to maintain euglycemia and the rate of glucose
utilization (Rd) were decreased in OLZ-IV, whereas endogenous
glucose production (EGP) rate was increased compared with
vehicle-IV. Consistent with an elevation in EGP, the OLZ-IV group
had higher hepatic mRNA levels for the enzymes glucose-6-
phosphatase and phosphoenolpyruvate carboxykinase. Phos-
phorylation of hypothalamic AMP-activated protein kinase
(AMPK) was increased in OLZ-IV rats compared with controls.
Similarly, an intracerebroventricular infusion of OLZ resulted in
a transient increase in glycemia as well as a higher Ra in the basal
period. During the hyperinsulinemic period, OLZ-ICV caused a
decreased GIR, an increased EGP, but no change in Rd. Further-
more, OLZ-ICV rats had increased hepatic gluconeogenic en-
zymes and elevated hypothalamic neuropeptide-Y and agouti-
related protein mRNA levels.
CONCLUSIONS—Acute central nervous system exposure to
OLZ induces hypothalamic AMPK and hepatic insulin resistance,
pointing to a hypothalamic site of action for the metabolic
dysregulation of atypical antipsychotics. Diabetes 59:2418–
2425, 2010
A
typical antipsychotics, such as olanzapine
(OLZ), account for the majority of antipsy-
chotic drugs prescribed for the treatment of
schizophrenia and bipolar disorders. Further-
more, a multicenter double-blind comparison between
several antipsychotics has underscored the efﬁcacy of OLZ
compared with other earlier-generation antipsychotics
(1). However, atypical antipsychotics, in particular OLZ,
have been associated with serious metabolic side ef-
fects, including weight gain, dyslipdemia, and diabetes
(2,3).
Although it is established that atypical antipsychotics,
especially OLZ, are strongly associated with increased
weight gain in humans, little is known regarding the
mechanisms responsible for this effect (4). Acutely, two
atypical antipsychotics, clozapine and OLZ, increase the
consumption of a high-calorie fat emulsion in rodents (5).
Further, weight gain in rats treated for 7 days with OLZ
was accounted for by increased food intake (6). However,
hyperphagia and weight gain are not universally observed
in animal models of antipsychotic treatment, but increased
body adiposity is strongly associated with chronic OLZ
administration (7,8).
In general, body adiposity positively correlates with
insulin resistance. Indeed, short-term (4 weeks) treatment
with OLZ caused increased visceral adiposity, which was
associated to markedly reduced hepatic insulin sensitivity
(9,10), a common feature of obesity and type 2 diabetes.
However, recent evidence (11–13) suggests that OLZ can
acutely impair insulin sensitivity, in the absence of
changes in adiposity. OLZ, as well as other atypical anti-
psychotics, acts as an antagonist for many neurotransmitter
receptors, including dopamine, serotonin, histamine, and
acetylcholine (14,15). To date, the identity and location of
the receptors blocked by OLZ that are implicated in the
disruption of glucose metabolism remain unknown. The
hypothalamus has long been implicated in the regulation
of energy balance as well as glucose homeostasis. Circu-
lating hormones and nutrients are acting in the hypothal-
amus, and speciﬁcally the arcuate nucleus (ARC), to
modulate glucose metabolism (16). One likely site of
action for the deleterious effects of OLZ on glucose
homeostasis is in the ARC, since several receptors for
which OLZ has moderate to high afﬁnity are expressed in
this hypothalamic area. Both serotonin and dopamine can
inhibit ﬁring in ARC neurons (17), whereas D2 receptor
agonists reduce and antagonists increase the expression of
ARC neuropeptide-Y (NPY) (18). In addition, serotoniner-
gic inputs in ARC are shown to regulate NPY/AgRP neu-
rons (19), supporting the notion that OLZ might affect
energy balance and glucose homeostasis by modulating
the activity of these neurons. In this regard, peripheral
administration of OLZ in mice is able to acutely induce
phosphorylation of hypothalamic AMP-activated protein
kinase (AMPK), whose activation has been linked to
increased expression of NPY/AgRP. NPY/AgRP neurons
have been implicated in the control of glucose homeosta-
sis and, more speciﬁcally, the regulation of hepatic insulin
sensitivity (20). This study examines whether central
nervous system (CNS) delivery of OLZ can affect periph-
eral glucose homeostasis and insulin action.
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Animal model and surgical procedures. Male Sprague-Dawley rats (250–
275 g), purchased from Charles River Laboratories (Wilmington, MA), were
acclimated to our facilities for 7 days before undergoing surgical catheteriza-
tions of the left jugular vein and right carotid artery, as previously described
(21). A set of rats also received intracerebroventricular cannulae targeting the
third ventricle (from Bregma-anterior-posterior: 2.2 mm; dorsal-ventral:
7.5 mm from sagital sinus surface; medial-lateral: 0.0 mm). The jugular
catheter served for infusions and the carotid catheter for blood sampling. Rats
were allowed to recover for at least 6–10 days after surgery before the clamp
studies. The correct placement of the intracerebroventricular cannulae was
veriﬁed by the induction of a drinking response to 30 ng angiotensin II
intracerebroventricularly performed 4 days after the surgery. All animal
procedures were approved by the institutional animal care and use committee
of the University of Cincinnati.
Olanzapine dosing. The dose of intravenous infusion of OLZ (OLZ-IV group)
was selected according to two criteria: 1) the extent of occupancy of the D2
receptors (80–90%) achieved with a single dose (14,22) and 2)i tw a s
experimentally determined to cause only moderate sedation (up to grade 2
according to the Sedation Rating Scale in Salamone et al. [ 23]). In addition,
since the plasma half-life of OLZ in rats is eightfold shorter than humans
(22,24), we used a primed-continuous infusion in order to study its effect on
steady-steady condition and minimize pharmacokinetic ﬂuctuations (24). A
stock solution of OLZ (provided by Eli Lilly, Indianapolis, IN, and the National
Institute of Mental Health Chemical Synthesis and Drug Supply Program) was
prepared in HCl (0.1 N). Working solutions of OLZ were prepared daily by
dissolving the stock solution in saline (0.9%) or artiﬁcial cerebrospinal ﬂuid
(Harvard Apparatus, Holliston, MA) for intravenous (3 ml) or intracerebro-
ventricular (15 l) infusions, respectively. Final solutions were adjusted to pH
5.5–6.0 with sodium hydroxide (0.5 N). Control animals received saline (0.9%)
or artiﬁcial cerebrospinal ﬂuid after pH adjustment to 5.5–6.0 as well.
Hyperinsulinemic-euglycemic clamp. Sixty minutes before the drug infu-
sion (t  60), a prime-continuous infusion of [
3H-3]-glucose (Perkin-Elmer
NEN, Boston, MA) was initiated and maintained throughout the study (prime
5.2 Ci/min for 4 min, then 0.52 Ci/min). At 0 min, a prime-continuous
infusion of OLZ or vehicle was started and maintained throughout the study.
A total of 4.5 mg/kg was delivered intravenously (prime 375 g/kg/min for 4
min, then 25 g/kg/min) and 330 g/rat was delivered intracerebroventricu-
larly (prime 22 g/min for 5 min, then 1.9 g/min). At 60 min, after collecting
the last blood sample for the basal period, all rats received 1) a prime-
continuous infusion of human insulin (prime 44.3 mU/kg for 1 min, then 2.5
mU/kg/min) and 2) a variable infusion of 25% glucose solution to maintain
euglycemia. Blood samples for glucose concentration and speciﬁc activity
were taken every 10 min during the basal period and the last hour of the clamp
period. Larger blood samples were taken at 0, 30, 60, 120, 150, and 180 min and
stored for subsequent analysis. To prevent anemia, erythrocytes from the
blood samples were washed, resuspended in saline solution, and reinfused.
The rate of glucose infusion was adjusted as needed in order to clamp the
plasma glucose concentration at 130–140 mg/dl. Plasma radioactivity from
[
3H-3]-glucose was determined after deproteinization with Ba(OH)2 and ZnSO4
and subsequent evaporation to remove tritiated water, as described (25).
Clamp parameters calculations. Since OLZ administration induced a tran-
sient increase in the plasma glucose levels during the basal period, we applied
the non–steady-state Steele equation (26) to determine the rate of glucose
appearance (Ra) and disappearance (Rd):
Ra 
F  pV  [(Glu1  Glu2)/2]  [(SA2  SA1)/(t2  t1)]
(SA1  SA2)/2
Rd  Ra 
pV  (Glu2  Glu1)
t2  t1
where F equals tracer infusion rate (dpm/min/kg), p equals correction factor
(0.65), and V equals volume of distribution of glucose (0.25 l/kg). Glu1 and
Glu2 equal glucose concentration (mg/ml) at time t1 and t2 (min). SA1 and SA2
(dpm/mg) equal glucose-speciﬁc activities at times t1 and t2. The mean values
of Ra and Rd during basal (60–120 min) and clamp (140–180 min) periods were
used for comparison between groups. The endogenous glucose production
(EGP) rate was calculated as the difference between Rd and the glucose
infusion rate (GIR).
Biochemistry methods. Plasma glucose concentrations were measured by
the glucose oxidase method using a GM7 Micro-Stat Analyzer (ANALOX
Instruments, London, U.K.). Insulin levels in plasma were determined by
radioimmunoassay. Plasma free fatty acid (FFA) concentration was deter-
mined using a colorimetric kit (Wako Chemicals).
Gene expression methods. Liver and hypothalamus were harvested imme-
diately after the completion of the hyperinsulinemic clamps. Total RNA was
isolated by using a TRIzol reagent (Invitrogen) and reverse transcribed into
cDNA by using the SuperScript III First-Strand Synthesis System for RT-PCR
(Invitrogen) according to the manufacturer’s directions. Quantitative real-time
PCR was carried out on the iCycler (Bio-Rad). Brieﬂy, each 20 l SYBR green
reaction consisted of 1–5 l cDNA (210 ng/l), 10 l iQ SYBR green
Supermix (Bio-Rad), 1 lo f4mol/l forward and reverse primers and 3–7 l
nuclease-free water. PCR was performed with the following cycling condi-
tions: 40 cycles of 10 s at 95°C and 30–60 s at 56–62°C. Speciﬁcity of the PCR
product was conﬁrmed by examination of dissociation reaction plots. A
distinct single peak indicated that a single DNA sequence was ampliﬁed during
PCR. Primers were as follows: -tubulin: forward TACCCTCGCATCCACT
TCCCT, reverse CGCTTGGTCTTGATGGTGGCA; glucose-6-phosphatase
(G6Pase): forward CTTGTCAGGCATTGCTGTGGC, reverse CAGGAGGTC
CACCCCTAGCC; PEPCK: forward ATTCTGCACCCCTGCCAGC, reverse AA
CACCCCATGCTGCCAGC; AgRP: forward GCAGAAGGCAGAAGCTTTGGC,
reverse CCCAAGCAGGACTCGTGCAG; NPY: forward TACTCCGCTCTGCGA
CACTACATC, reverse CACATGGAAGGGTCTTCAAGCC; proopiomelanocor-
tin: forward AGTGCCAGGACCTCACCACG, reverse AAGCGGTCCCAGCG
GAAG; prepro-melanocyte-stimulating hormone (MCH): forward TTCCCAG
CTGAGAATGGAGTTCAG, reverse CCCAGCATACACCTGAGCATGTC; and
prepro-orexin: forward AGAAGACGTGTTCCTGCCGT, reverse CGTGGTT
ACCGTTGGCCTGAA.
Tissue extraction and Western blotting. Hypothalami were homogenized
in freshly prepared ice-cold buffer (150 mmol/l NaCl, 50 mmol/l Tris pH 8.0,
0.1% SDS, 0.5% deoxycholate, and 1% Triton X-100, radioimmunoprecipitation
assay buffer modiﬁed) with one tablet of protease inhibitor cocktail (catalog
no. 04693124001; Roche) and 100 l of phosphatase inhibitor cocktail Set II
(catalog no. 524625; Calbiochem) per 10 ml of buffer. The samples were spun
down for 10 min at 14,000 rpm and the supernatant sonicated in a fresh tube
four times for 5 s. The insoluble material was removed by centrifugation
(14,000 rpm) for 20 min at 4°C. Aliquots of the resulting supernatants
containing 400 g total proteins were diluted in Laemmli sample buffer and
boiled for 5 min before electrophoresis separation. For immunoblot analysis,
40 g of protein from denatured extracts was separated by SDS-PAGE (150
min at 110 V constant) using a miniature-slab gel apparatus (Bio-Rad).
Electrotransfer of proteins from the gel to polyvinylidene ﬂuoride membranes
(Bio-Rad) was performed (60 min at 100 V constant at 4°C) and blotted with
speciﬁc antibodies, anti–phospho-AMPK and anti–AMPK (catalog no. 2535 and
no. C2532, respectively; Cell Signaling Technology) and anti–-tubulin (cata-
log no. MAB380; Millipore). Band intensities were quantiﬁed by optical
densitometry of developed radiographs (Quantity One 1-D Analysis Software;
Bio-Rad).
Statistical analysis. All data are presented as means  SE. Plasma glucose,
insulin, and FFA levels were analyzed by two-way ANOVA, followed by the
Duncan post hoc test for multiple comparisons when appropriate. Student t
test for independent samples was performed to the others parameters
described here. The statistical calculations were performed using Statistica
6.1 software (StatSoft, Tulsa, OK).
RESULTS
Intravenous infusion of OLZ before and during a
hyperinsulinemic-euglycemic clamp. Both OLZ and ve-
hicle groups had similar body weight (vehicle: 317.0 
6.3 g vs. OLZ: 316.1  6.0 g), food intake (vehicle: 123.6 
4.9 Kcal vs. OLZ: 114.8  5.9 Kcal), and adiposity (epidid-
ymal pads, vehicle: 2.165  0.18 g vs. OLZ: 2.198  0.08 g).
Intravenous infusion of OLZ transiently increased plasma
glucose levels during the basal period compared with rats
receiving vehicle [two-way repeated-measures ANOVA
group effect, OLZ-IV vs. vehicle: F(1,224)  6.0, P  0.02;
group 	 time interaction effect: F(14,224)  5.7, P 
 0.0001]
(Fig. 1A). Although the peak in plasma glucose levels was
observed 30 min after the start of OLZ administration,
there were no differences in the plasma insulin levels
during basal or clamp periods between OLZ-IV– and
vehicle-treated groups [two-way repeated-measures
ANOVA group effect, OLZ-IV vs. vehicle: F(1,70)  0.61, P 
0.05; group 	 time interaction effect: F(5,70)  0.42, P 
0.05] (Fig. 1B). In addition, OLZ increased plasma FFAs,
although at the end of the hyperinsulinemic period there
was no difference between vehicle- and OLZ-IV–treated
groups [two-way repeated-measures ANOVA group effect,
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 0.01; group 	 time
interaction effect: F(5,80)  2.06, P  0.07] (Fig. 1C).
During the basal period, the rate of glucose appearance
(Ra) was higher (t test  2.40, P  0.02) in OLZ-infused
animals compared with vehicle (Fig. 2A). During the clamp
period, the infusion rate of exogenous glucose (GIR)
required to maintain euglycemia was signiﬁcantly lower (t
test  4.33, P 
 0.001) in the OLZ group (Fig. 2B),
indicating that OLZ decreased insulin sensitivity. Tracer
analysis during the clamp period showed that the insulin
resistance in OLZ-IV rats was the result of a reduced
glucose disposal rate (Rd)( t test  3.10, P 
 0.01) and an
increased EGP (t test  3.4, P 
 0.01) compared with the
vehicle group (Fig. 2C and D).
Consistent with the increased EGP, the mRNA levels of
hepatic G6Pase (t test  3.55, P 
 0.01) and PEPCK (t
test  2.62, P  0.01) were higher in the OLZ-IV group
compared with control (Fig. 2E and F).
Since these studies were conducted in male rats, in a
separate experiment in mice, we tested whether the acute
effect of OLZ on glucose and FFA levels is sex speciﬁc.
Intraperitoneal injection of OLZ cause signiﬁcant hyper-
glycemia and increased FFA levels in both male and
females mice (supplemental Fig. 1 in the online appendix,
available at http://diabetes.diabetesjournals.org/cgi/content/
full/db10-0449/DC1).
Intracerebroventricular infusion of OLZ before and
during a hyperinsulinemic-euglycemic clamp. Similar
to the OLZ-IV studies, intracerebroventricular infusion of
OLZ (OLZ-ICV) transiently increased plasma glucose levels
during the basal period compared with rats receiving ICV
vehicle [two-way repeated-measures ANOVA group effect,
OLZ-ICV vs. vehicle: F(1,224)  12.23, P 
 0.01; group 	
time interaction effect: F(14,224)  7.57, P 
 0.0001] (Fig.
3A). Both groups had similar body weight (vehicle: 329.3 
4.4 g vs. OLZ: 325.0  4.5 g), food intake (vehicle: 123.7 
2.8 Kcal vs. OLZ: 132.3  4.4 Kcal), and adiposity (vehicle:
2.30  0.11 g vs. OLZ: 2.248  0.09 g). Like in the
intravenous studies, OLZ-ICV increased plasma glucose
levels in the basal period, with peak values observed 30
min after the bolus of OLZ. Plasma insulin levels during
basal or clamp periods were not changed signiﬁcantly
between OLZ-ICV and vehicle groups [two-way repeated-
measures ANOVA group effect, OLZ-ICV vs. vehicle: F(1,50)
 1.25, P  0.28; group 	 time interaction effect: F(5,50) 
0.54, P  0.74] (Fig. 3B). Additionally, there were no
signiﬁcant differences in the plasma FFAs between the
groups during the basal or hyperinsulinemic periods [two-
way repeated-measures ANOVA group effect, OLZ-ICV vs.
vehicle: F(1,60)  3.51, P  0.08; group 	 time interaction
effect: F(5,60)  1.10, P  0.37] (Fig. 3C).
During the basal period, the OLZ-ICV group had a higher
Ra (t test  2.79, P  0.01) compared with the vehicle
group (Fig. 4A). During the clamp period, the GIR was
decreased in the OLZ-ICV group compared with the vehi-
cle group (t test  4.24, P 
 0.001) (Fig. 4B). The
decreased insulin sensitivity of the OLZ-ICV group was
accounted for by a higher EGP (t test  3.30, P 
 0.01)
(Fig. 4D) compared with the vehicle group. However,
unlike the OLZ-IV studies, the rate of glucose disposal (Rd)
of the OLZ-ICV group was not changed compared with
control (t test  0.85, P  0.40) (Fig. 4C).
Moreover, intracerbroventricular infusion of OLZ signif-
icantly increased gene expression of G6Pase (t test  3.18,
P 
 0.01) and tended to increase PEPCK expression (t
test  1.75, P  0.09) (Fig. 4E and F).
Hypothalamic effects of intravenous and intracer-
broventricular OLZ. The phosphorylation of AMPK in
hypothalamus of OLZ-IV rats was signiﬁcantly increased (t
test  2.59, P  0.01) (Fig. 5A and B), indicating that
peripheral acute administration of OLZ activates hypo-
thalamic AMPK signaling. Despite this activation, we did
not detect any change in the levels of NPY or AgRP
mRNAs (supplemental ﬁg. 2). However, OLZ-ICV signif-
icantly increased expression of hypothalamic NPY (t
test  2.88, P  0.01) and AgRP (t test  3.27, P 
 0.01)
mRNA levels compared with vehicle rats without chang-
ing the mRNA levels of orexin, MCH, and proopiomela-
nocortin (Fig. 5C).
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FIG. 1. Time course (means  SE) of plasma levels of glucose (A),
insulin (B), and FFAs (C) during basal and hyperinsulinemic-euglyce-
mic clamp periods. Minute 0 represents sampling before a prime-
continuous (a bolus of 1.5 mg/kg and 1.0 mg/kg/h) intravenous (IV)
infusion of OLZ (OLZ-IV, n  10) or vehicle (n  8) *Statistics denote
comparison to respective 0 min and vehicle time point. Two-way
ANOVA followed by Duncan test, P < 0.05.
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In the present study, we show that acute infusion of OLZ
either intravenously or intracerbroventricularly induces
hepatic insulin resistance. These metabolic alterations are
accompanied by hypothalamic activation of AMPK and
increased expression of NPY and AgRP. These ﬁndings are
consistent with the notion that insulin resistance associ-
ated with the administration of OLZ could, at least in part,
be secondary to its effects on the central nervous system.
Treatment with atypical antipsychotics increases the
risk of weight gain, diabetes, and other metabolic disor-
ders in comparison to ﬁrst-generation antipsychotic drugs
(1–3,27). Recent studies (28–30) have also shown that
some atypical antipsychotics affect glucose homeostasis
before changes in body weight are observed, suggesting
that insulin resistance could occur before or independent
of any change in adiposity. We showed here that in lean,
male rats an acute intravenous infusion of OLZ induced a
transient increase of plasma glucose levels (Fig. 1A)i nt h e
absence of a compensatory insulin response (Fig. 1B). In
several studies, increases in plasma glucose levels have
been observed after acute administration of several differ-
ent atypical antipsychotics in mice. These effects were
blocked by a glanglionic blocker, an 2 adrenergic recep-
tor antagonist, or a glucocorticoid receptor antagonist,
suggesting a central activation of the sympathetic system
(31–33).
Although in humans OLZ-induced obesity and diabetes are
not sex speciﬁc (34), early studies have preferentially used
female rodents because of an apparent stronger sensitivity to
OLZ in causing obesity (6,10). Recent ﬁndings and our data
show that male rats, and mice of both genders, are similarly
at risk for OLZ-induced alterations in body weight and
glucose homeostasis (supplemental Fig. 1) (8,35).
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FIG. 2. Effects of intravenous infusion of OLZ (OLZ-IV, n  10) or vehicle (n  8) on (means  SE) glucose appearance rate (Ra)( A), GIR (B),
glucose disappearance rate (Rd)( C), and EPG (D) before and during stead-state hyperinsulinemic-euglycemic clamp condition. Liver (E),
G6Pase, and PEPCK (F) mRNA levels (means  SE) of rats intravenously (iv) infused with OLZ following the hyperinsulinemic-euglycemic clamp.
*Statistics denote comparison to vehicle group; t test, P < 0.05.
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after chronic or acute peripheral administration, as shown
in hyperglycemic clamp experiments (9,12). We did not
detect a change in insulin levels during the basal period of
OLZ infusion, despite the fact that intravenous OLZ in-
creased glycemia. The lack of an increase in insulin
secretion in response to increased plasma glucose during
the OLZ infusion might be related to sympathetic inhibi-
tion of insulin release from pancreatic -cells, as previ-
ously suggested (32).
Under hyperinsulinemic-euglycemic clamp conditions,
which allowed us to override potential differences in
insulin secretion, we found lower rates of exogenous
glucose infusion and glucose utilization (GIR and Rd) and
higher EGP in OLZ-IV–infused rats (Fig. 2B–D). These data
support the hypothesis that acutely administered OLZ
induces insulin resistance. Our observations agree with
previous studies showing impairment of insulin action on
hepatic glucose production and peripheral glucose utiliza-
tion after a subcutaneous bolus injection of OLZ (11–13).
In addition, here we showed that OLZ-induced insulin
resistance was associated with higher gene expression
levels of G6Pase and PEPCK, indicating that OLZ im-
pairs the ability of insulin to suppress the expression of
rate-limiting enzymes for hepatic glucose output (Fig.
2E and F).
To test the hypothesis that OLZ impairs insulin sen-
sitivity through CNS action, we infused OLZ intracere-
broventricularly before and during hyperinsulinemic-
euglycemic clamps. Indeed, intracerebroventricular
OLZ infusion increased the rate of glucose appearance
(Ra) during the basal period, impaired the ability of
insulin to suppress EGP (Fig. 4A and D), and decrease
the expression of gluconeogenic enzymes in liver (Fig.
4E and F).
Interestingly, like OLZ-IV, OLZ-ICV markedly impaired
hepatic insulin action but did not increase plasma FFAs
or impair glucose disposal. Under basal and low insulin
levels, OLZ-IV infusion increased plasma FFA levels.
However, during hyperinsulinemia, the elevated FFA
levels gradually return to control levels (Fig. 1C). This
ﬁnding agrees with previous reports showing no differ-
ences in FFA levels after the hyperinsulinemic-euglyce-
mic clamp condition in rats (11). Nonetheless, in our
OLZ-IV studies, we observe a time-dependent and tran-
sient increase in FFA levels. Similarly, we found that
acute intraperitoneal administration of OLZ in male and
female mice increases plasma FFA levels, an effect that
was not blocked by pretreatment with a 3-blocker
(supplemental Fig. 1D and E). The effect of OLZ on FFA
levels has been reported in studies with more prolonged
treatment. Healthy men receiving daily OLZ treatment
for 8 days display an impaired ability of hyperinsulin-
emia to reduce plasma FFA levels and increase Rd,i n
the absence of changes in body weight and adiposity
(36). Thus, the reported lack of effect on FFA plasma
levels (11) could be due to differences in time of
sampling and/or OLZ route of administration.
It is known that elevated plasma FFA levels impair the
ability of insulin to suppress hepatic glucose production
and stimulate glucose uptake by skeletal muscle (37).
However, we observed that only OLZ-IV administration
increased plasma FFAs (Fig. 1C) and impaired insulin-
stimulated Rd (Fig. 2C), while OLZ effects on hepatic
glucose production occurred regardless of the route of
administration and the presence of increased plasma FFA
levels (Fig. 2D and Fig. 4D). These data suggest that
increased FFA levels do not explain the deleterious effects
of OLZ on glucose production.
Our data suggest that the effect of OLZ on FFA and
glucose utilization may be mediated by peripheral recep-
tors. In support of this notion, recent studies have shown
that OLZ reduced basal and isoproterenol-stimulated re-
lease of FFAs in rat adipocytes, as well as glucose uptake
(38,39).
Hepatic insulin resistance is a common feature of
obesity and type 2 diabetes (37,40) and may result not
only from alterations of insulin signaling in the liver but
also from impaired insulin action in the brain. Neuronal
circuitry responsive to insulin play an important role in
modulating hepatic gluconeogenesis in response to
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FIG. 3. Time course (means  SE) of plasma levels of glucose (A),
insulin (B), and FFAs (C) during basal and hyperinsulinemic-euglyce-
mic clamp periods. Minute 0 represents sampling before a prime-
continuous (a bolus of 110 g and 73.4 g/h) intracerebroventricular
(icv) infusion of OLZ (OLZ-ICV, n  8) or vehicle (n  10). *Statistics
denote comparison to respective 0 min and vehicle time-point. Two-
way ANOVA followed by Duncan test, P < 0.05.
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insulin receptor activation inhibits NPY/AgRP neurons
and stimulates proopiomelanocortin neurons in order to
control energy homeostasis (42). Furthermore, insulin
action on arcuate neurons suppresses hepatic glucose
production by a mechanism dependent on phosphatidyl-
inositol kinase–ATP-sensitive K channel activation
(43).
Intracerebroventricular administration of OLZ in-
creased hypothalamic mRNA levels of NPY and AgRP
(Fig. 5C) in rats killed after2ho fhyperinsulinemic-
euglycemic clamps. This result suggests a potential
mechanism by which CNS OLZ reduced hepatic insulin
sensitivity. Insulin inhibits arcuate NPY and AgRP gene
expression and inhibits AMPK phosphorylation/activity
(44), whereas inhibition of insulin action in the hypo-
thalamic arcuate nucleus increases the expression of
NPY and AgRP (45). Conversely, atypical antipsychot-
ics, including clozapine and OLZ, increase phosphoryla-
tion/activity of AMPK (46). In our intravenous studies,
OLZ increases hypothalamic AMPK phosphorylation,
suggesting that this atypical antipsychotic might coun-
teract the action of insulin on NPY/AgRP neurons by
preventing the insulin-mediated inhibition of AMPK.
However, unlike intracerebroventricular OLZ, we did
not detect increased expression of NPY/AgRP in the
OLZ-IV studies. Several studies with peripheral injection
of OLZ have failed to ﬁnd changes in NPY/AgRP levels
(6,47), although several lines of evidence show that
peripheral OLZ acutely activates ARC neurons (48). We
speculate that our ﬁnding of increased NPY/AgRP in
ICV-OLZ and not in OLZ-IV can be explained by a greater
time of neuronal exposure to OLZ in the intracerebro-
ventricular group. Since OLZ can transiently activate
AMPK in hypothalamic explants (46), our results in
OLZ-IV rats are consistent with an acute activation of
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FIG. 4. Effects of intracerebroventricular (icv) infusion of OLZ (OLZ-ICV, n  8) or vehicle (n  10) on (means  SE) glucose appearance rate
(Ra)( A), GIR (B), glucose disappearance rate (Rd)( C), and EPG (D) before and during stead-state hyperinsulinemic-euglycemic clamp condition.
Liver (E), G6Pase, and PEPCK (F) mRNA levels (means  SE) of rats intracerebroventricularly infused with OLZ following the hyperinsulinemic-
euglycemic clamp. *Statistics denote comparison to vehicle group; t test, P < 0.05.
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expression. Taken together, our data support the hy-
pothesis that OLZ counteracts the inhibitory action of
insulin on hypothalamic AMPK in NPY/AgRP neurons.
Intracerebroventricular administration of NPY impairs
insulin’s ability to suppress hepatic glucose production
(49,50). In addition, selective ablation of the insulin
receptor in AgRP-positive neurons leads to hepatic
insulin resistance (20). Taken together, these data sup-
port the notion that atypical antipsychotics alter hepatic
insulin sensitivity by impairing insulin’s action on NPY/
AgRP neurons.
In conclusion, we have shown that acute administration
of OLZ induces insulin resistance in the absence of
changes in food intake and body composition. In agree-
ment with previous studies (9,13), this effect is primarily
due to hepatic insulin resistance. These effects are accom-
panied by the activation of hypothalamic AMPK. More-
over, we showed that CNS delivery of OLZ induces hepatic
insulin resistance and activates hypothalamic NPY/AgRP
neurons. These data are consistent with the notion that the
deleterious effects of OLZ on hepatic insulin action are
mediated at least in part by impaired hypothalamic control
of hepatic glucose metabolism.
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